Significant advancements in lung cancer treatment were observed throughout 2024, with new drug approvals and promising clinical trial results. The phase 1 INSIGHT-003 trial of efti, pembrolizumab, and chemotherapy for first-line advanced nonsquamous NSCLC has completed enrollment, indicating a step forward in treatment options.
In the realm of acute myeloid leukemia (AML), a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated AML has shown promising findings, as discussed by Amandeep Salhotra, MD.
The SURPASS-ET trial demonstrated the superior efficacy of ropeginterferon alfa-2b over anagrelide in patients with essential thrombocythemia, achieving higher durable response rates and greater reduction in JAK2 allele burden.
FDA approvals in 2024 included subcutaneous nivolumab for solid tumors and tiselizumab for advanced gastric and GEJ cancers, alongside key breakthroughs in breast cancer treatment. Experts provided perspectives on treatment choices for gastric adenocarcinoma and ctDNA monitoring in HER2-positive breast cancer.
Pancreatic ductal adenocarcinoma remains a challenge due to its complex biology and resistance mechanisms. Meanwhile, the potential of repurposing old drugs for cancer treatment is being explored, highlighting the need for investment in this area.
In gynecologic cancer, potential practice-changing therapies include the combination of carboplatin, paclitaxel, and PD-1 blockade, and the use of fam-trastuzumab deruxtecan-nxki in endometrial cancer.
A new drug application for dordaviprone for recurrent H3K27M-mutant diffuse glioma treatment was submitted to the FDA, indicating ongoing efforts to address challenging cancer types.
The FDA accepted and granted priority review to an NDA for avutometinib plus defactinib in recurrent KRAS-mutated low-grade serous ovarian cancer, supported by promising data.
Paxalisib received FDA indication that its overall survival data could support standard approval in glioblastoma, based on findings from the GBM-AGILE study.
A biologics license application for TLX250-CDx was submitted to the FDA, supported by the phase 3 ZIRCON trial showing high accuracy for ccRCC detection.
Lastly, the establishment of docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil as the preferred regimen for patients with localized adenocarcinoma marks a significant development in cancer treatment protocols.